Module

New Data on Hepatitis B Virus Treatment

Source: Hepatitis Annual Update 2004

New Data on Hepatitis B Virus Treatment


Program Director: John P. Phair, MD

Faculty:

  • Robert P. Perrillo, MD

CME CREDIT INFORMATION

Release Date: 09/10/04

Expiration Date: 09/09/05


Physicians: maximum of 1 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Review other anti-HBV drugs that are currently in clinical trials, including telbivudine, entecavir, and clevudine.

  • Describe drugs with anti-hepatitis B virus (HBV) activity that are already approved for other indications, including peginterferons, tenofovir disoproxil fumarate, emtricitabine, and thymosin alpha-1.

  • Discuss preclinical anti-HBV agents.


Content includes:

  • Currently Available Treatments
  • Interferon alfa
  • Pegylated Interferon
  • Nucleoside Analogues
  • Lamivudine
  • Adefovir Dipivoxil
  • Emtricitabine (FTC)
  • Tenofovir Disoproxil Fumarate
  • Agents Under Development
  • Alternative Nucleoside Analogues
  • Telbivudine & Valtorcitabine
  • Clevudine
  • Other Analogues
  • Immunologic Modifiers
  • Gene Therapy
  • Viral Packaging Inhibitors
  • Innovative Therapeutic Approaches
  • Combination Nucleosides
  • Combination Interferon and Nucleoside Analogue Therapy
  • Viral Resistance and Combination Nucleoside Analogues
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.

Educational grant provided by:

Educational grants support only the CME-certified components of this program.